Explore 3 Stock Ideas & Industry Insights Download Free Report

Healthcare

LSE:CLBX Drops 5.95% as Investors Weigh Cancer Diagnostics Growth and Cash Burn

CelLBxHealth has moved into focus afterLSE:CLBX fell 5.95% on 16 September 2026.

Ankur Sharma | 16 September 2026

Proteome Sciences Stock Slides 5.17%: What Investors Are Watching After Its Latest Update?

Proteome Sciences has moved into focus on16 September 2026, withLSE:PRM down 5.17%.

Ankur Sharma | 16 September 2026

ImmuPharma Stock News: P140 Patent Filing and MASH Research Put LSE:IMM in Focus

ImmuPharma is back in focus afterLSE:IMM gained 6.08%, with the latest move coming against a backdrop of several important scientific, intellectual-property and corporate developments.

Ankur Sharma | 16 September 2026

Coiled Therapeutics Stock Falls 7.29% as Investors Await AO-252 Clinical Milestones

Coiled Therapeutics plc LSE:COIL is in focus after its shares fell7.29% on 16 September 2026, despite the company having several important clinical-development milestones ahead.

Ankur Sharma | 16 September 2026

Why Is Futura Medical Stock Rising Today? LSE:FUM Gains 8.31% Amid Strategic Review

Futura Medical LSE:FUM has attracted renewed attention after rising8.31% on 16 September 2026. The move comes during an unusually important period for the company, with several strategic and financial developments taking place simultaneously.

Ankur Sharma | 16 September 2026

Is Eden Research Stock in Focus After Fresh International Approvals and Stronger Revenue?

Eden Research is attracting attention because the company is moving through an important commercialisation phase for its sustainable crop-protection technologies.

Ankur Sharma | 16 September 2026

PHSC Stock Slides 9.10%: Revenue Growth Meets Profitability Pressure as Investors Watch FY27

PHSC Plc has moved into focus on16 September 2026, withLSE:PHSC down 9.10%in the market snapshot.

Ankur Sharma | 16 September 2026

Provexis Stock News: What Is Driving the 6.08% Move in LSE:PXS?

Provexis is attracting attention afterLSE:PXS gained 6.08%in the latest market snapshot. The move comes as investors continue to assess the company's progress in commercialising Fruitflow and improving its financial performance.

Ankur Sharma | 16 September 2026

How GSK’s New Cancer Asset Is Adding Another Development Programme to the FTSE 100 Group’s Pipeline

GSK (LSE:GSK) secured worldwide rights to a trispecific T-cell engager being developed for multiple myeloma, a blood cancer. The molecule is designed to engage T cells alongside two tumour-associated antigens, and GSK (LSE:GSK) has described it as a "potential best-in-class" candidate with an improved …

Ankur Sharma | 16 September 2026

Why FTSE 250 Stocks Genus (LSE:GNS), CVS Group (LSE:CVSG) and Spire Healthcare (LSE:SPI) Put Healthcare and Life Sciences in Focus

Genus sits at an unusual intersection of biology and agriculture. Through its PIC porcine division and ABS bovine business, it supplies breeding animals, semen and embryos to pig and cattle producers in more than 25 countries, using genomics to improve traits such as feed …

Ankur Sharma | 16 September 2026
Support

Hi! How can we help you today?

Loading…